GlobeNewsWire
05 Jun 2026, 15:38 UTC · 2h ago
ROSEN, LEADING INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP
GlobeNewsWire
05 Jun 2026, 15:38 UTC · 2h ago
Story key points
3 claims · impact-rated
A securities class action lawsuit has been filed against Immutep Ltd. alleging false or misleading statements regarding the TACTI-004 trial. — Legal challenges alleging fraud or concealment of clinical trial risks typically create significant downward pressure on biotech stock prices.
-0.60The lawsuit claims Immutep was aware that internal data increased the risk that the TACTI-004 study would fail to meet primary efficacy and/or safety endpoints. — Allegations that a core clinical trial is likely to fail directly threaten the company's pipeline value and future revenue potential.
-0.50The lead plaintiff deadline for the Immutep class action is July 6, 2026. — Deadlines for lead plaintiff appointments keep the legal narrative active in the market, though they have less immediate price impact than the original filing.
-0.10Ticker attribution
Continue reading
6 related stories
Top 3 movers · tap to explore
Model heads
The company is facing a securities class action lawsuit alleging it made false or misleading statements regarding clinical trial prospects.
The law firm is investigating potential securities claims on behalf of the company's shareholders.
The company is the subject of a class action lawsuit announcement.
No ticker relationship head found.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
4 dimensions · 9 clusters
Market reaction
0 bid · 10 offered
No stock impact ranking available yet.
PRNewsWire
10h ago
